- West Virginia University School of Pharmacy
- Pharmaceutical Sciences
Program 3: Alexander B. Osborn Hematopoietic Malignancy and Transplantation
Ten most recent:
Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities.
Shay G, Hazlehurst LA, Lynch CC.
J Mol Med (Berl). 2016;94(1):21-35.
A preclinical assay for chemosensitivity in multiple myeloma.
Khin ZP, Ribeiro ML, Jacobson T, Hazlehurst LA, Perez L, Baz R, Shain K, Silva AS.
Cancer Res. 2014;74(1):56-67.
MTI-101 (cyclized HYD1) binds a CD44 containing complex and induces necrotic cell death in multiple myeloma.
Gebhard AW, Jain P, Nair RR, Emmons MF, Argilagos RF, Koomen JM, McLaughlin ML, Hazlehurst LA.
Mol Cancer Ther. 2013;12(11):2446-2458.
Development of highly potent and selective diaminothiazole inhibitors of cyclin-dependent kinases.
Schonbrunn E, Betzi S, Alam R, Martin MP, Becker A, Han H, Francis R, Chakrasali R, Jakkaraj S, Kazi A, Sebti SM, Cubitt CL, Gebhard AW, Hazlehurst LA, Tash JS, Georg GI.
J Med Chem. 2013;56(10):3768-3782.
The one-two punch: combination treatment in chronic myeloid leukemia.
Sweet KL, Hazlehurst LA, Pinilla-Ibarz J.
Crit Rev Oncol Hematol. 2013;88(3):667-679.
CRM1 inhibition sensitizes drug resistant human myeloma cells to topoisomerase II and proteasome inhibitors both in vitro and ex vivo.
Turner JG, Dawson J, Emmons MF, Cubitt CL, Kauffman M, Shacham S, Hazlehurst LA, Sullivan DM.
J Cancer. 2013;4(8):614-625.
Emerging strategies for targeting cell adhesion in multiple myeloma.
Nair RR, Gebhard AW, Emmons MF, Hazlehurst LA.
Adv Pharmacol. 2012;65:143-189.
Role of STAT3 in Transformation and Drug Resistance in CML.
Nair RR, Tolentino JH, Hazlehurst LA.
Front Oncol. 2012;2:30
Potentiation of Nilotinib-mediated cell death in the context of the bone marrow microenvironment requires a promiscuous JAK inhibitor in CML.
Nair RR, Tolentino JH, Argilagos RF, Zhang L, Pinilla-Ibarz J, Hazlehurst LA.
Leuk Res. 2012;36(6):756-763.
Acquisition of resistance toward HYD1 correlates with a reduction in cleaved alpha4 integrin expression and a compromised CAM-DR phenotype.
Emmons MF, Gebhard AW, Nair RR, Baz R, McLaughlin ML, Cress AE, Hazlehurst LA.
Mol Cancer Ther. 2011;10(12):2257-2266.
1997-1999 NIH NSRA post-doctoral fellowship, “Isolation of A Selected Drug Resistant Gene”
2000-2001 Multiple Myeloma Research Foundation junior fellowship, “The role of CDK2 in fibronectin induced regulation of p27 levels
2011 Educational Session: Emerging Opportunities for Targeting CAM-DR AACR. Orlando, FL
2014 Invited for oral presentation at SBIR investor forum for November 11th , Santa Clara California
2015 Invited platform presentation at the NCI investor forum southeast region, Durham, NC
Post-doctoral Training- University of Arizona and the Moffitt Cancer Center
Graduate Training - Ph.D., Cell and Molecular Biology University of Vermont, 1994
About Lori A Hazlehurst
Dr. Hazlehurst earned her Ph.D. from the Cell and Molecular Biology Program at the University of Vermont. Her post-doctoral studies were performed at the University of Arizona and the Moffitt Cancer Center. Her studies focused on developing strategies for targeting the tumor microenvironment to increase the efficacy of standard of care agents. Her current research focus is to develop strategies for targeting Ca2+ homeostasis in cancer. The laboratory focus is translational with an overall goal of developing novel therapeutic strategies for the treatment of cancer.
1999- 2001 Research Assistant Professor, University of South Florida, College of Medicine Department of Interdisciplinary Oncology
2001- 2002 Research Assistant Professor, University of Arizona
2002- 2007 Assistant Professor, University of South Florida, College of Medicine, Department of Interdisciplinary Oncology
2008-2015 Associate Member Moffitt Cancer Center
2011-Present Modulation Therapeutics Co-Founder
Program 3: Alexander B. Osborn Hematopoietic Malignancy and Transplantation Co-Leader
Grants and Research
R21 CA191981 Specific skeletal targeting of MMP-2 for the treatment of multiple myeloma
1R01CA195727-01 Targeting CD44-mediated calcium signaling for the treatment of relapsed myeloma